DENODO
23.6.2022 09:03:13 CEST | Business Wire | Press release
Denodo , the leader in data management, today announced that its customer LeasePlan, headquartered in the Netherlands and with business operations across the globe, has been chosen as the winner of the IDC’s 2022 European Data Strategy & Innovation Awards in the Data Management Excellence category. The winners were announced on June 9th, 2022 at the special awards ceremony as part of IDC’s 2022 European Data and Intelligence Summit in Sintra, Portugal.
IDC's European Data Strategy & Innovation Awards are focused on celebrating the European organizations that are blazing trails in this area and on improving awareness of "what works". According to Neil Ward-Dutton, VP AI, Automation and Analytics Europe, at IDC, "This is the third year of our European Data Strategy and Innovation Awards, and we were delighted to receive so many high-quality nominations from across the region."
IDC received 34 nominations for 3 award categories and LeasePlan edged past the other nominees in the Data Management excellence category to win the coveted title. According to IDC, "Nominations in this category were from enterprises that could demonstrate significant advances in their ability to manage data effectively and efficiently at scale. The overall winner was LeasePlan, for its creation of a logical data fabric across all its key data sources, which has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs."
LeasePlan, one of the world’s leading Car-as-a-Service companies, has approximately 1.9 million vehicles under management in 29 countries. These vehicles generate a large amount of data that has to be integrated and contextualized to support the customer journey. What followed was LeasePlan’s next-gen data strategy, envisioned to encompass a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access, to be supported by a Global Data Hub. According to Sumit Arya, the Head of Data and Solution Architecture at LeasePlan, “The Logical Data Fabric built on the Denodo Platform is a critical component of LeasePlan’s Global Data Hub to seamlessly build a foundation for data self-service and simplify transparent data migration. It has enabled us to create new business services and best support our drivers on every step of their journey.” Denodo Platform has also supported the data governance needs of the organization and facilitated its cloud modernization efforts with zero downtime for BI reporting while migrating legacy data marts to the Cloud in various business units across geographies.
“We want to congratulate our customer LeasePlan for its efforts and the innovative use of the Denodo Platform to support its data management needs and key business initiatives,” said Ravi Shankar, Senior Vice President and Chief Marketing Officer at Denodo. “The Denodo Platform provides an abstraction layer to create a single, secure point-of-entry to LeasePlan's entire data ecosystem. LeasePlan has also built a centralized framework for data governance by leveraging the metadata management and data catalog capabilities of the Denodo platform to ensure the highest level of self-service and data security. We are thrilled to see LeasePlan credited for the way they have applied our platform to make such an impact.”
Please Tweet : https://ctt.ac/hUnsp
About LeasePlan
LeasePlan, one of the world’s leading Car-as-a-Service companies, is transforming from an analogue to a fully digital business model. LeasePlan worked with Denodo and other technologies to create a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access. This gives a foundation for data self-service and simplifies transparent data migration to the Cloud. Most notably, the data fabric approach has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005168/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom